









Markets
/
Stocks
/
nasdaq-algs
/

Aligos Therapeutics Inc

ALGS

7.330USD

+0.120+1.66%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

50.95MMarket Cap

LossP/E TTM



Aligos Therapeutics Inc

7.330

+0.120+1.66%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aligos Therapeutics Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aligos Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

111 / 407

Overall Ranking

241 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

87.000

Target Price

+1106.66%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aligos Therapeutics Inc Highlights

StrengthsRisks

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.94M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.94M.

Fairly Valued

The company’s latest PE is -0.55, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.72M shares, decreasing 34.47% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 52.54K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 5.99, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 965.00K, representing a year-over-year decrease of 9.05%, while its net profit experienced a year-over-year decrease of 413.44%.

Score

Industry at a Glance

Previous score

5.99

Change



Financials

6.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.49

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Aligos Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 8.75, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.55, which is -46.44% below the recent high of -0.30 and -967.56% above the recent low of -5.89.

Score

Industry at a Glance

Previous score

8.75

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 111/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Aligos Therapeutics Inc is 50.00, with a high of 175.00 and a low of 36.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

87.000

Target Price

+1106.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Aligos Therapeutics Inc

ALGS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 5.73, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 10.01 and the support level at 5.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.86

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.581

Sell

RSI(14)

30.403

Neutral

STOCH(KDJ)(9,3,3)

6.470

Oversold

ATR(14)

0.771

Low Volatility

CCI(14)

-126.787

Sell

Williams %R

92.950

Oversold

TRIX(12,20)

-0.758

Sell

StochRSI(14)

25.712

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

7.704

Sell

MA10

8.539

Sell

MA20

9.291

Sell

MA50

9.865

Sell

MA100

9.075

Sell

MA200

10.398

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 50.84%, representing a quarter-over-quarter decrease of 31.03%. The largest institutional shareholder is The Vanguard, holding a total of 139.78K shares, representing 2.61% of shares outstanding, with 6.49% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Woodline Partners LP

518.30K

+64.34%

Deep Track Capital LP

444.11K

Roche Holding AG

441.04K

-0.00%

Alyeska Investment Group, L.P.

412.00K

Sio Capital Management, LLC

335.94K

+85.89%

Tang Capital Management, LLC

141.13K

Adage Capital Management, L.P.

140.00K

-69.89%

The Vanguard Group, Inc.

Star Investors

139.78K

-0.69%

Readystate Asset Management LP

136.78K

+201.28%

Blatt (Lawrence M)

84.82K

-1.34%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.51, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 2.77. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.